Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.

CXCR4–CXCL12 axis blockade with ulocuplumab safe in relapsed/refractory myeloma

24 Feb 2020

The first-in-class fully human IgG4 monoclonal antibody ulocuplumab that inhibits the binding of CXCR4 to CXCL12 appears to be safe in the treatment of patients with relapsed/refractory myeloma, yielding a high response rate when added to lenalidomide and dexamethasone with acceptable adverse events (AEs), according to the results of a phase Ib/II trial.

The trial included 46 patients (median age, 60 years), 30 of which were enrolled in arm A (ulocuplumab alone and in combination with lenalidomide and dexamethasone) and 16 in arm B (bortezomib and dexamethasone).

The median number of prior therapies was three, with 70 percent of the patients having received more than the median. This trial involved a dose-escalation and a dose-expansion part, and researchers applied a 3+3 design on both treatment arms. Ulocuplumab dose was increased to a maximum of 10 mg/kg without reaching the maximum tolerated dose.

Frequently reported treatment-related AEs were neutropoenia in arm A (13 patients, 43.3 percent) and thrombocytopoenia in arm B (six patients, 37.5 percent). There were documented deaths related to study drugs.

Efficacy data favoured arm A. The group of patients treated with the combination of ulocuplumab plus lenalidomide and dexamethasone achieved higher rates of response (partial response or better; 55.2 percent) and clinical benefit (72.4 percent) compared with the group given bortezomib and dexamethasone (25.0 percent and 50.0 percent, respectively). The efficacy advantage in arm A was observed even in patients previously exposed to immunomodulatory agents.

The findings indicate that CXCR4 inhibitors are a promising class of antimyeloma drugs that merit further investigation in clinical trials, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.